Abstract. This study assessed the incidence of cytomegalovirus (CMV) disease and associated outcomes after oral ganciclovir prophylaxis in renal transplantation. A retrospective analysis was performed of all adult renal transplant recipients at a single transplant center transplanted between August 16, 1996, and December 31, 2000. CMV disease prophylaxis included ganciclovir 1000 mg orally thrice daily prescribed for 90 d in DϪ/Rϩ cases and 180 d in Dϩ/RϪ and Dϩ/Rϩ cases. Forty (9.1%) of 470 patients studied were diagnosed with CMV disease, which varied significantly by CMV serostatus and number of HLA-DR matches. The highest incidence of disease, 26.2%, was in Dϩ/RϪ patients with zero HLA-DR matches. Five-year graft survival was 56.8% with CMV disease compared with 79.1% without (P Ͻ 0.001). Five-year graft survival with CMV disease was 75.9% with one or two HLA-DR matches versus 16.2% with zero HLA-DR matches (P Ͻ 0.001). CMV remains an important factor in long-term graft survival after oral ganciclovir prophylaxis. However, we have observed that the adverse impact of CMV disease on graft survival is apparent only in patients with zero HLA-DR matches. These results call for the development of new CMV disease prophylaxis and treatment strategies in patients with zero HLA-DR matches. In addition, organ allocation policies discouraging combining CMV-seropositive donors and zero HLA-DR matches may be worth consideration.
In a study performed at our transplant center, we demonstrated the efficacy of oral ganciclovir prophylaxis to reduce the incidence of CMV viremia and symptomatic CMV disease in renal transplant recipients (1) . CMV viremia was reduced from 100% in untreated patients to 11% in treated patients during prophylaxis. Overall symptomatic CMV disease incidence was 61% in untreated patients and 21% in patients treated with oral ganciclovir prophylaxis after the completion of a 3-mo prophylaxis regimen. Although the incidence of symptomatic CMV disease was significantly reduced by prophylaxis, it was remarkable that disease occurred more commonly when the donor was CMV-seropositive compared with seronegative. We subsequently extended our prophylaxis to 90 d in D -/Rϩ cases and 180 d in Dϩ/RϪ and Dϩ/Rϩ cases. The long-term consequences of the CMV disease that did occur were unknown.
We and others have observed variations in the incidence, severity, and consequences of viral activity in solid organ transplantation related to HLA matching (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) . Several authors have observed that the incidence of CMV disease was more common when certain HLA antigens were present (3,6 -8,10 -13) . We have observed that certain matched and mismatched HLA antigens are associated with increased graft loss rates from CMV sero-mismatching (2) .
To determine the long-term impact of short term oral ganciclovir prophylaxis, the development of CMV disease, and the impact of donor and recipient HLA matching, we have undertaken a retrospective review of the outcomes of patients treated at our center with a uniform oral ganciclovir CMV-prophylaxis regimen. CMV disease incidence and patient survival outcomes were assessed through 5 yr posttransplant. The effect of HLA matching on the observed outcomes was assessed.
Materials and Methods

Patients
This study was designed as a retrospective analysis of all adult renal transplant recipients at a single transplant center, Barnes-Jewish Hospital at the Washington University Medical Center, St. Louis, Missouri. All patients transplanted at the center from August 16, 1996 , through December 31, 2000, were considered for analysis and were included in the study if it was the intention of the transplant physicians to treat them with the CMV disease prophylaxis regimen described below. The first patient transplanted under this regimen received a transplant on August 16, 1996 , and all subsequent transplant recipients were transplanted under this regimen through the end of the study period and were included in the study.
CMV Disease Prophylaxis
The treatment plan for transplant recipients with either CMVseropositive donor (Dϩ) or recipient (Rϩ) status included 1000 mg of ganciclovir orally thrice daily without adjustment for renal function for CMV disease prophylaxis. This was prescribed for 90 d in DϪ/Rϩ cases and 180 d in Dϩ/RϪ and Dϩ/Rϩ cases. DϪ/RϪ cases did not receive CMV disease prophylaxis.
CMV Disease Diagnosis and Treatment
As previously described, CMV disease was defined as a symptomatic CMV syndrome associated with CMV viremia as detected by PCR (1, 17) . CMV syndrome was defined by at least one of the following: fever (Ͼ38.3°C for two or more days within a 7-d period without another explanation), leukopenia (Ͻ4 ϫ 10 9 WBC/L on two consecutive occasions), thrombocytopenia (Ͻ150 ϫ 10 9 /L on two consecutive occasions), unexplained elevated serum creatinine, unexplained debilitating fatigue in association with detection of CMV viremia by PCR, and evidence of other tissue invasive CMV, obtained as clinically indicated. Patients diagnosed with CMV disease were treated with 5 mg/kg ganciclovir intravenously every 12 h for 21 d with adjustments for renal insufficiency, leukopenia, or thrombocytopenia.
Immunosuppressive Therapy
Recipients of two-haplotype matched living related donor kidneys received triple immunosuppressive therapy with cyclosporine or tacrolimus, azathioprine, and prednisone (n ϭ 20). With few exceptions (n ϭ 16), all other transplant recipients received quadruple immunosuppressive therapy with interoperative induction of polyclonal antithymocyte globulin (Atgam [Upjohn, Kalamazoo, MI] or Thymoglobulin [SangStat, Fremont, CA]) for 3 to 7 d, azathioprine, cyclosporine or tacrolimus, and prednisone (Table 1) . A small number of patients (n ϭ 10) were enrolled in a clinical trial that compared basiliximab (Novartis Pharmaceuticals, Basil, Switzerland) (n ϭ 5) to placebo (n ϭ 5) with maintenance immunosuppression of cyclosporine, mycopeholate mofetil (CellCept, Hoffman-La Roche, Nutley, NJ), and prednisone (Basiliximab trial reference US 305, Novartis Pharmaceuticals [unpublished] ). Four additional patients received basiliximab induction therapy, and three patients received induction therapy with murine anti-CD3 monoclonal antibody (OKT3, muromonab; Orthobiotech, Raritan, NJ). Mycophenolate mofetil was substituted for azathioprine in patients believed to be at high risk of acute rejection or with contraindications to azathioprine: panel reactive antibody Ͼ 20%, repeat transplant, immunologic cause of endstage renal disease, or gout requiring allopurinol. Cyclosporine doses were adjusted to maintain 12-h whole blood trough levels between 150 to 400 ng/ml, and tacrolimus doses were adjusted to maintain trough levels between 3 to 10 ng/ml (18) . Substitutions and deletions were made to this regimen in select patients with contraindications. Further adjustments in immunosuppression were made on the basis of the clinical status of the patient including CMV disease, other infections, or rejection.
Statistical Analyses
Differences in the characteristics of patients were tested with t test for continuous variables, Fisher's exact test for binary categorical variables, 2 for multicategorical variables, and the Mantel-Haenszel 2 for ordered multicategorical variables. Incidence of CMV disease, graft loss, and death were calculated using survival analysis techniques. Univariate survival analysis was performed with the KaplanMeier methodology. Multivariate survival analysis was performed with Cox regression. Stepwise variable selection techniques were used for all multivariate estimates. All statistical tests were two-tailed. P-values were required to be less than 0.05 for significance. 
Results
Patients
During the study period, 470 patients received kidney transplants and were included in the study. No patients were withdrawn from CMV prophylaxis for any reason during the study. Characteristics of recipients, donors, and immunosuppressive therapy are presented in Table 1 .
CMV Disease Incidence
Forty patients were diagnosed with CMV disease for an incidence of 9.1%. First episodes of CMV disease occurred between 19 and 518 d posttransplant. The incidence of CMV disease by CMV sero-pairing is shown in Figure 1 . There was a significant association of donor CMV serostatus when the recipient was CMV-seronegative. When the donor was seropositive and the recipient seronegative (Dϩ/RϪ) there was 22.2% incidence of CMV disease compared with a 4.1% incidence in DϪ/RϪ pairings (P Ͻ 0.001).
In contrast, we observed an apparently counterintuitive ordering of CMV disease incidence in Dϩ/Rϩ (5.2%) and DϪ/Rϩ (9.2%) seropairings. (P ϭ 0.16). The reason for this is unknown but may be due to the longer duration of ganciclovir prophylaxis in Dϩ/Rϩ cases. HLA sero-matching was not a factor (see below).
Overall incidence of CMV disease was not significantly associated with HLA-DR matching with 14 cases (11.1%) of CMV disease in 126 patients with zero HLA-DR matches and 26 cases (7.6%) of CMV disease in 344 patients with one or two HLA-DR matches (P ϭ 0.262). However, a novel finding of our study was that not only was CMV donor seropositivity important for the development of CMV disease; CMV disease incidence was also strongly associated with HLA-DR matching when the donor was CMV-seropositive. Indeed, the incidence of disease was more than twice the incidence of disease associated with zero HLA-DR matches and one or two HLA-DR matches, 16.7% versus 8.0% for a relative risk of 210% (P ϭ 0.03).
Additionally, there appeared to be a double CMV exposure effect for the risk of CMV disease associated with decreased HLA donor and recipient matching. When both the donor and recipient were CMV seropositive, the incidence of CMV disease was 10.8% for zero HLA-DR matches and 3.0% for one and two HLA-DR matches for a relative risk of 360% (P ϭ 0.04). In contrast, we did not observe higher CMV disease incidence in Dϩ/RϪ cases associated with zero HLA-DR matches, 26.2% compared with one and two HLA-DR matches, 20.2%, with a relative risk of 130% (P ϭ 0.39). No significant relationship between CMV disease incidence and HLA-DR matching was observed in other individual CMVseropairings, DϪ/Rϩ and DϪ/RϪ. Furthermore, no other characteristics of recipients, donors, or immunosuppression treatments were significantly associated with CMV disease incidence.
Sixty-nine patients (14.7%) experienced one or more acute rejection episodes. Nine of these patients were diagnosed with both CMV disease and acute rejection (22.5%). We observed no evidence that CMV disease was a significant cause of subsequent acute rejection with a 14.0% incidence of acute rejection in patients without CMV disease and a 16.2% incidence of acute rejection subsequent to CMV disease (P ϭ 0.81). In six cases, CMV disease preceded acute rejection; in two cases, acute rejection preceded CMV disease; in one case, the diagnoses were simultaneous. Twenty-two patients (15.1%) with zero HLA-DR matches and 47 patients (14.5%) with one or two HLA-DR matches had one or more acute rejection episodes (P ϭ 0.88).
Graft Survival
With death considered as a graft loss, overall graft survival through 5 yr posttransplant was 71.6%. CMV sero-pairing was not significantly associated with differences in graft survival with 5-yr survival rates of 69.7% in Dϩ/Rϩ, 69.1% in Dϩ/ RϪ, 77.2% in DϪ/Rϩ, and 71.2% in DϪ/RϪ cases (P ϭ 0.51). In patients with functioning grafts at 6 mo posttransplant, beyond the end of all oral ganciclovir prophylaxis, CMV disease was associated with 56.8% graft survival compared with 79.1% graft survival in patients without CMV disease (P Ͻ 0.001) as shown in Figure 2 .
A dramatic effect of HLA-DR mismatching was observed in patients with a CMV disease diagnosis as shown in Figure 3 . In patients who had a CMV disease diagnosis and who had functioning grafts through 6 mo posttransplant, 5-yr survival was 87.5% for two HLA-DR matches, 61.1% for one HLA-DR match, and 16.2% for zero HLA-DR matches (P ϭ 0.002). There was no significant difference in graft survival after 6 mo in patients diagnosed with CMV disease between one and two HLA-DR matches for a combined graft survival of 75.9% (P ϭ 0.47), which was not significantly different from the graft Figure 1 . Incidence of cytomegalovirus (CMV) disease by CMV sero-pairing. There was a significant association of donor CMV serostatus when the recipient was CMV-seronegative: 4.1% incidence in DϪ/RϪ pairings and a 22.2% incidence in Dϩ/RϪ pairings (P Ͻ 0.001). Donor CMV serostatus was not significantly associated with CMV disease incidence when the recipient was CMV-seropositive: 5.2% incidence in Dϩ/Rϩ pairings and a 9.2% incidence in D-/Rϩ pairings (P ϭ 0.16). The apparently counterintuitive ordering of CMV disease incidence in Dϩ/Rϩ and DϪ/Rϩ cases may be due to the longer prophylaxis period in Dϩ/Rϩ cases: with 3 mo for DϪ/Rϩ cases and 6 mo for Dϩ/Rϩ cases. survival in all patients without a CMV disease diagnosis (P ϭ 0.55). Thus, in cases with grafts surviving at least 6 mo, patients with zero HLA-DR matches and a diagnosis of CMV disease compared with all others had a 395% increase in the risk of graft loss by 5 yr posttransplant (P Ͻ 0.001).
There was no significant association between HLA-DR matching and graft survival after 6 mo in patients without a diagnosis of CMV disease as shown in Figure 4 . Furthermore, no significant effects of HLA-A or -B matching were observed for patients with or without a CMV disease diagnosis.
Risk of CMV Associated Graft Loss
To determine the impact of donor CMV serostatus on graft survival, we compared the graft survival effect of zero HLA-DR matches for recipients of CMV-seropositive versus CMV-seronegative kidneys with functioning grafts at 6 mo posttransplant. We observed a significant effect on graft survival when the donor was CMV-seropositive and HLA-DR matching in recipients with functioning grafts at 6 mo posttransplant. Graft survival was 62.6% for zero HLA-DR matches and 79.9% for one or two HLA-DR matches (P ϭ 0.04). In contrast, we observed nearly identical 5-yr graft survival between recipients with functioning grafts at 6 mo posttransplant and CMV-seronegative donors for zero HLA-DR matches (DϪ/0 HLA-DR match; 84.2%) versus one or two HLA-DR matches (DϪ/1 to 2 HLA match; 84.3%; P ϭ 0.76). However, one and two HLA-DR matches were not significantly different in either case.
Supporting Analyses
Analyses censored at death with function produced results similar to those presented above. Multivariate analysis confirmed the results for all-cause and death-censored graft failure. In no case did we observe a significant difference between one and two HLA-DR matches and thus grouped these results in all reported analyses. However, the results are similar, if considerably more complex, when using the three HLA-DR matching groups. No significant differences in results were noted in living compared with cadaveric donor transplants. No significant differences were observed in maintenance immunosuppression at transplant discharge, at the time of CMV disease, or at the last date of follow-up, either by HLA-DR matching or by CMV serology or by CMV disease groupings or combinations. In patients who had a CMV disease diagnosis and who had functioning grafts through 6 mo posttransplant, 5-yr survival was 87.5% for two HLA-DR matches, 61.1% for one HLA-DR match, and 16.2% for zero HLA-DR matches (P ϭ 0.002). There was no significant difference in graft survival after 6 mo in patients diagnosed with CMV disease between one and two HLA-DR matches for a combined graft survival of 75.9% (P ϭ 0.47), which was not significantly different from the graft survival in all patients without a CMV disease diagnosis (P ϭ 0.55). Thus, in cases with grafts surviving at least 6 mo, patients with zero HLA-DR matches and a diagnosis of CMV disease compared with all others had a 395% increase in the risk of graft loss by 5 yr posttransplant (P Ͻ 0.001). Figure 4 . Graft survival and HLA-DR matching in patients without CMV disease. There was no significant association between HLA-DR matching and graft survival after 6 mo in patients without a diagnosis of CMV disease.
Discussion
We have shown an important graft survival impact of CMV disease after oral ganciclovir prophylaxis in renal transplantation. However, we have observed that this effect is isolated to patients who have zero HLA-DR matches with their donor. Furthermore, recipients with zero HLA DR matches and CMVseropositive donors are at increased risk of CMV disease. Combined, we have observed that recipients of CMV-seropostive, zero HLA-DR matched kidneys are at a considerably increased risk of CMV associated graft loss.
This study is a retrospective epidemiologic study of patients receiving transplants in a single center. There are important limitations associated with such a study design. Although it is a benefit of this study that a single ganciclovir CMV prophylaxis regimen and a uniform immunosuppression regimen were in place throughout the study period, this study cannot determine the effects of potential variations in these protocols on the observed results. It is possible that variations in the CMV prophylaxis and immunosuppression regimens could alter the magnitude of the effects observed here. In particular, polyclonal antibody immunosuppression was used in the large majority of patients in this study. Although no significant effect of antibody immunosuppression was found, this may be due to the small number of patients in the comparison group who did not receive antibody therapy. It is also possible that specifics of the management of CMV disease or the patient population are associated with the magnitude of the results. Although a properly designed clinical trial could provide evidence of such effects, it is highly unlikely that a clinical trial designed to assess the results observed in this study would have been performed without the evidence presented here. It may be reasonable to perform such a trial specifically designed to address the center-specific weaknesses of this study. However, additional retrospective studies performed at centers with varying immunosuppression and CMV prophylaxis protocols may be sufficient to validate and determine variations in the effects observed here. The results of such retrospective studies could be available considerably sooner than the results of a prospective study.
Acute rejection is an important predictor of poor graft survival. A recent study by Becker et al. (19) has reported an association between CMV and acute rejection. In that study, patients diagnosed with symptomatic CMV disease, by our definition, were more than twice as likely to experience subsequent acute rejection. In our study, we observed no causal relationship between CMV disease and subsequent acute rejection. The majority of patients in Becker's study did not receive oral ganciclovir prophylaxis, whereas all but CMV DϪ/RϪ patients in our study did. It is possible that oral ganciclovir prophylaxis reduces the incidence of acute rejection attributable to CMV disease. However, further study will be required to verify this conjecture.
Interestingly, we observed HLA matching effects only for HLA-DR and not HLA-A or B, suggesting these effects are associated with MHC class II but not class I molecules. This may help direct investigations into mechanism of the interaction between CMV and HLA-DR matching.
The alarmingly inferior graft survival in association with CMV disease and poor HLA-matching calls for increased attention to prophylactic and other management strategies for CMV disease in zero HLA-DR matched patients. Although possible mechanisms of the relationship between CMV disease and HLA-DR matching are only theories at this time (20) , longer duration ganciclovir prophylaxis, prophylaxis with alternative or additional agents, and modified immunosuppression protocols may provide benefit. Indeed our observed lower incidence of CMV disease in the Dϩ/Rϩ group (5.2%) compared with the DϪ/Rϩ (9.2%) group supports prolonged prophylaxis as one means of ameliorating the negative impact of HLA mismatching in those at risk for development of CMV disease since the Dϩ/Rϩ group received 6 mo of prophylaxis compared with the DϪ/Rϩ group that received 3 mo of prophylaxis. However, further study including clinical investigations and examinations of the virology and pathology of the effects observed here will be required to determine the benefits of these and other management strategies.
Although further study will be required to quantify patient's preferences for waiting and donor selection relative to CMV serology and HLA-DR matching, the results presented here may call for incorporation of alternative organ allocation schemata. As the waiting list for cadaveric kidneys grows, there is pressure to increase the importance of waiting time and downplay the importance of HLA matching in the allocation mechanism. However, our results show considerable importance for HLA-DR matching when the donor is CMV-seropositive, particularly if the potential recipient is CMV-seronegative. A patient who has waited many years for a kidney transplant deserves the best care available. We may be able to do considerably better for a patient then offering them a zero HLA-DR matched transplant in cases of higher risk of CMV disease. This is especially true for a patient near the top of the waiting list, who can expect a relatively short wait for another offer.
